中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

96 records (took 0.021 seconds)

    Composition and method for maintaining non-enveloped viral vectors
    62.
    发明申请
    Composition and method for maintaining non-enveloped viral vectors 审中-公开
    用于维持非包膜病毒载体的组合物和方法

    公开(公告)号：US20030153065A1

    公开(公告)日：2003-08-14

    申请号：US10046517

    申请日：2002-01-14

    Applicant: GenVec, Inc.

    Inventor： Imre Kovesdi ,  Stephen C. Ransom

    IPC: C12N007/01

    CPC classification number: C12N7/00 ,  C12N2710/10351

    Abstract: The invention provides a composition and a method for preserving a non-enveloped viral vector. The composition comprises (a) trehalose, (b) a divalent metal salt, a cationic polymer, or a combination thereof, (c) a multiplicity of non-enveloped viral vector particles, and (d) a liquid carrier. Non-enveloped virus particles are stable in the composition in a liquid form, at elevated temperatures, for a sustained period of time.

    Abstract translation: 本发明提供了一种用于保存非包膜病毒载体的组合物和方法。 组合物包含（a）海藻糖，（b）二价金属盐，阳离子聚合物或其组合，（c）多个非包膜病毒载体颗粒，和（d）液体载体。 无包膜的病毒颗粒在液体形式的组合物中在高温下持续持续一段时间是稳定的。

    Method of identifying a gene product
    63.
    发明申请
    Method of identifying a gene product 有权
    识别基因产物的方法

    公开(公告)号：US20030143609A1

    公开(公告)日：2003-07-31

    申请号：US10336702

    申请日：2003-01-03

    Applicant: GenVec, Inc

    Inventor： Miguel E. Carrion ,  Imre Kovesdi

    IPC: C12Q001/68 ,  C12Q001/70

    CPC classification number: C12N15/86 ,  C12N15/1055 ,  C12N2710/10343 ,  C12Q1/6816 ,  C12Q1/6897 ,  C12Q2563/167

    Abstract: The present invention provides a method of identifying a gene product. The method comprises providing a multiplicity of cells comprising a first gene product. Preferably, the first gene product is produced in the multiplicity of cells by expressing a first exogenous nucleic acid sequence encoding the first gene product. A library of second nucleic acid sequences encoding second gene products is then introduced into the multiplicity of cells. The second nucleic acid sequences are expressed in the multiplicity of cells to produce the second gene products such that the first gene product and at least one of the second gene products contact. The method further comprises causing a complex to form between the first gene product, an affinity molecule that binds the first gene product, and at least one of the second gene products, and subsequently retrieving the complex. At least one second gene product of the complex then is identified.

    Abstract translation: 本发明提供鉴定基因产物的方法。 该方法包括提供包含第一基因产物的多个细胞。 优选地，通过表达编码第一基因产物的第一外源核酸序列，在多种细胞中产生第一基因产物。 然后将编码第二基因产物的第二核酸序列的文库导入多个细胞。 第二核酸序列在多重细胞中表达以产生第二基因产物，使得第一基因产物和第二基因产物中的至少一个接触。 所述方法还包括使第一基因产物，结合第一基因产物的亲和分子与至少一种第二基因产物形成复合物，随后检索该复合物。 然后鉴定该复合物的至少一个第二基因产物。

    E1-revertant-free adenoviral composition
    64.
    发明申请
    E1-revertant-free adenoviral composition 审中-公开
    E1无反应蛋白腺病毒组合物

    公开(公告)号：US20030087438A1

    公开(公告)日：2003-05-08

    申请号：US10001097

    申请日：2001-11-02

    Applicant: GenVec, Inc.

    Inventor： Douglas E. Brough ,  Imre Kovesdi

    IPC: A61K048/00 ,  C12N015/861 ,  C12N007/02 ,  C12N007/00

    CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N2710/10343

    Abstract: The invention provides a composition comprising particles of an adenoviral vector comprising deficiencies in two or more gene functions required for viral replication, wherein at least one of the deficiencies is of a gene function of the E1 region of the adenoviral genome and (b) a carrier therefor, with relatively high ratios of (i) the number of particles of the adenoviral vectors to the number of particles of E1-revertant replication-deficient adenoviral vectors not comprising one or more of the deficiencies in gene functions of the E1 region of the adenoviral and (ii) the number of particles of the adenoviral vectors to the number of particles of replication-competent adenoviral vectors, as well as a method of preparing such a composition.

    Abstract translation: 本发明提供包含腺病毒载体颗粒的组合物，其包含病毒复制所需的两个或多个基因功能的缺陷，其中至少一个缺陷是腺病毒基因组的E1区域的基因功能，和（b）载体 因此，具有相对高的比例（i）腺病毒载体的颗粒数与E1复发缺失型复制缺陷型腺病毒载体的颗粒数量不包含腺病毒E1区的基因功能的一个或多个缺陷 和（ii）腺病毒载体的颗粒数与复制能力的腺病毒载体的颗粒数目，以及制备这种组合物的方法。

    Materials and methods for treating ocular-related disorders
    65.
    发明申请
    Materials and methods for treating ocular-related disorders 审中-公开
    用于治疗眼部相关疾病的材料和方法

    公开(公告)号：US20030045498A1

    公开(公告)日：2003-03-06

    申请号：US10211701

    申请日：2002-08-02

    Applicant: GenVec, Inc.

    Inventor： Imre Kovesdi ,  Douglas E. Brough ,  Lisa Wei ,  Duncan L. McVey

    IPC: A61K048/00 ,  C12N015/85

    CPC classification number: C12N15/86 ,  A61K48/00 ,  A61K48/005 ,  A61K48/0075 ,  C07K14/71 ,  C07K14/811 ,  C12N2710/10343 ,  C12N2799/022

    Abstract: The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.

    Abstract translation: 本发明涉及一种预防性或治疗性地治疗动物至少一种与眼部相关的疾病，例如眼睛新生血管形成或年龄相关性黄斑变性的方法。 该方法包括使眼细胞与包含编码血管生成抑制剂的核酸序列和编码神经营养剂的相同或不同核酸序列的表达载体接触。 该方法还可以包括使眼细胞与不同的表达载体接触，每种表达载体包含编码血管生成抑制剂的核酸序列和/或编码神经营养剂的核酸序列。 此外，本发明提供了包含编码色素上皮衍生因子（PEDF）的核酸序列或其治疗片段的病毒载体。

    Non-adenoviral gene product-based complementing cells for adenoviral vectors
    66.
    发明申请
    Non-adenoviral gene product-based complementing cells for adenoviral vectors 有权
    用于腺病毒载体的非腺病毒基因产物互补细胞

    公开(公告)号：US20030017595A1

    公开(公告)日：2003-01-23

    申请号：US09911011

    申请日：2001-07-23

    Applicant: GenVec, Inc.

    Inventor： Douglas E. Brough ,  Jason G. D. Gall ,  Imre Kovesdi

    IPC: C12N015/861 ,  C12N007/01 ,  C12N005/08

    CPC classification number: C12N7/00 ,  C12N2710/10051 ,  C12N2710/10052 ,  C12N2710/10351 ,  C12N2710/10352

    Abstract: The invention provides cells and methods of using the cells for the propagation of replication-deficient adenoviral vectors. The cells comprise at least one heterologous nucleic acid sequence which upon expression produces at least one non-adenoviral gene product that complements in trans for a deficiency in at least one essential gene function of one or more regions of an adenoviral genome so as to propagate a replication-deficient adenoviral vector comprising an adenoviral genome deficient in the at least one essential gene function of the one or more regions when present in the cell.

    Abstract translation: 本发明提供了细胞和使用细胞促进复制缺陷型腺病毒载体的方法。 所述细胞包含至少一种异源核酸序列，其在表达时产生至少一种非腺病毒基因产物，所述非腺病毒基因产物在腺病毒基因组的一个或多个区域的至少一个必需基因功能缺陷中互补互补，从而传播 复制缺陷型腺病毒载体，其包含存在于细胞中时所述一个或多个区域的至少一个必需基因功能缺陷的腺病毒基因组。

    Fluorescence detection
    67.
    发明申请
    Fluorescence detection 有权
    荧光检测

    公开(公告)号：US20020045160A1

    公开(公告)日：2002-04-18

    申请号：US09888681

    申请日：2001-06-25

    Applicant: GenVec, Inc.

    Inventor： Miguel E. Carrion ,  Marilyn C. Menger

    IPC: C12Q001/70 ,  C12N013/00 ,  G01N033/558 ,  G01N033/559 ,  G01N033/561

    CPC classification number: G01N21/6486 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10351

    Abstract: The present invention provides methods of detecting and/or characterizing the viral vector particle content of a medium. A medium is provided and contacted with an excitation energy such that, if a viral vector particle is in the medium, an electron associated with the intrinsically fluorogenic portion of the viral vector particle will be raised to an excited energy state. The excited electron is permitted to emit radiation having an emission wavelength which is detected. The viral vector particle content of the medium then can be evaluated by comparing the detected emission wavelength with a standard signal. For example, the number of viral vector particles in a medium can be quantified by comparing the detected wavelength and its corresponding intensity to a standard signal. Similar methods for evaluating the adenoviral vector particle content of a medium and the intrinsically fluorogenic adenoviral structural protein content of a medium are provided.

    Abstract translation: 本发明提供了检测和/或表征介质的病毒载体颗粒含量的方法。 提供介质并与激发能接触，使得如果病毒载体颗粒在介质中，与病毒载体颗粒的固有荧光部分相关的电子将被升高到激发能态。 被激发的电子被允许发射具有检测到的发射波长的辐射。 然后可以通过将检测到的发射波长与标准信号进行比较来评估介质的病毒载体颗粒含量。 例如，可以通过将检测到的波长及其对应的强度与标准信号进行比较来量化介质中病毒载体颗粒的数量。 提供了用于评估培养基的腺病毒载体颗粒含量和介质的固有荧光腺病毒结构蛋白含量的类似方法。

    Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene
    69.
    发明申请
    Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene 失效

    公开(公告)号：US20020031823A1

    公开(公告)日：2002-03-14

    申请号：US09873486

    申请日：2001-06-04

    Applicant: GenVec, Inc.

    Inventor： Douglas E. Brough ,  Imre Kovesdi

    IPC: A61K048/00 ,  C12N015/86

    CPC classification number: C12N15/86 ,  C07K14/005 ,  C12N15/63 ,  C12N2710/10322 ,  C12N2710/10345 ,  C12N2710/16622 ,  C12N2830/60 ,  C12N2840/60

    Abstract: Provided are methods of modulating the persistence of the expression in a cell of a transgene, such as a transgene in a non-Herpes vector or in at least E4null adenoviral vector, and related systems. One method comprises contacting the cell with a non-Herpes vector comprising and expressing a gene encoding HSV ICP0, whereupon expression of HSV ICP0 the persistence of expression of the transgene is modulated. Further provided is a system for modulating the persistence of expression of a transgene, which system comprises a non-Herpes vector comprising (i) a gene encoding HSV ICP0 and (ii) a transgene, wherein the HSV ICP0 modulates the persistence of expression of the transgene and either the non-Herpes vector comprises the transgene or the system further comprises a vector, in which case the vector comprises the transgene. Another method comprises contacting the cell with an at least E4null adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, wherein the trans-acting factor modulates the persistence of expression of the transgene and the gene encoding the trans-acting factor is not from the E4 region of an adenovirus. Yet another method comprises contacting a cell simultaneously or sequentially with (i) an at least E4null adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. Also provided is a system for modulating the persistence of expression of a transgene in an at least E4null adenoviral vector, which system comprises (i) an at least E4null adenoviral vector comprising a transgene and (ii) a gene encoding a trans-acting factor, wherein the gene encoding the trans-acting factor is not from the E4 region of an adenovirus, the trans-acting factor modulates the persistence of expression of the transgene, and either the at least E4null adenoviral vector comprises the gene encoding the trans-acting factor or the system comprises a viral vector, in which case the viral vector comprises the gene encoding the trans-acting factor.

Patent Agency Ranking